Fused Multimodality Imaging

FMI Technologies Inc. (“FMI”) has developed an ultra high resolution diagnostic imaging technology that can be combined with drugs and molecular tracers for early detection and monitoring of neurodegenerative disorders. FMI’s PET/CT/SPECT system offers a superior and more cost-effective solution that enables advanced therapy and possible cures for Alzheimer’s disease, Vascular Dementia, Parkinson’s disease and other dementias. In addition, its unique Fused Multimodality Imaging will offer the data critical to earlier physician diagnosis of stroke, and head and neck cancers than are possible with current technology.

“Drugs need Imaging and Imaging needs Drugs” for early Asymptomatic Diagnostics and Personalized Medicine."

Disease Specific Imaging for Early Diagnosis and Therapy


*Neurologic Disease Specific High Definition Molecular and Anatomic Imaging for Early Memory Loss, Dementia, and Periodic Brain Health Diagnostics.*	Neurologic Disease Specific High Definition Molecular and Anatomic Imaging for "Healthy Brain" Diagnostics, Memory Loss, Dementia, Stroke,and other Dementias with Neurological Analysis Workstation and higher system throughput.
ScintiStar Neuro^TM 100 PET/CT/SPECT System	ScintiStar Neuro^TM 200 PET/CT/SPECT System
*Dense Breast High Definition 3D CT for Replacement of Diagnostic Mammography with "Non Contact" Imaging*	*Dense Breast High Defintion 3D CT and Molecular Imaging for Early Detection of Cancer and Image Guided Therapy.*

FMI's Patent Pending Platform Molecular and Anatomical Technology For Disease Specific Diagnostics and Therapy